Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-09-12
2006-09-12
Minnifield, Nita (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S450000, C424S236100, C424S277100, C424S254100, C424S240100, C514S002600, C514S008100, C530S350000
Reexamination Certificate
active
07105161
ABSTRACT:
A modulated immune response to an antigen is achieved by coadministering the antigen and a genetically-detoxifiedpertussisholotoxin, particularly one retaining its immunogenicity, to a host. The modulated immune response enables immunogenic compositions, including multivalent pediatric vaccines such as DTP, to be provided which produce a modulated immune response in the absence of extrinsic adjuvants such as alum. The adjuvanting effect achieved by the genetically-detoxifiedpertussisholotoxin enables at least the same level of adjuvanting effect to be achieved as previously attained by alum, without the undesirable side effects thereof.
REFERENCES:
patent: 5085862 (1992-02-01), Klein et al.
patent: 5182109 (1993-01-01), Tamura et al.
patent: 5221618 (1993-06-01), Klein et al.
patent: 5244657 (1993-09-01), Klein et al.
patent: 5332583 (1994-07-01), Klein et al.
patent: 5358868 (1994-10-01), Klein et al.
patent: 5773600 (1998-06-01), Burnette, III
patent: 5786189 (1998-07-01), Locht et al.
patent: 5932714 (1999-08-01), Loosmore et al.
patent: 5942418 (1999-08-01), Loosmore et al.
patent: 6109982 (2000-08-01), Okabe et al.
patent: 6140082 (2000-10-01), Loosmore et al.
patent: 6861410 (2005-03-01), Ott et al.
patent: 2003/0072774 (2003-04-01), Gajewczyk et al.
patent: 2003/0113345 (2003-06-01), Clements
patent: 2005/0158334 (2005-07-01), Contorni et al.
patent: 2005/0163746 (2005-07-01), Karmon et al.
patent: 352250 (1990-01-01), None
patent: 462534 (1991-12-01), None
Gajewczyk et al. FEMS Symposium No. 73, Bacterial Protein Toxins; 6thEuropean Workshop, Stirling, Scotland, UK, Jun. 27-Jul. 2, 1993. J Freer et al (eds) New York, 1994.
Boon, T. Scientific American. Mar. 1993, pp. 82-89.
Munoz et al. Microbiol Immunol 33:341-355, 1989 (Abstract).
Nencioni et al, Infection and Immunity, May 1990, 58/5:1308-1315.
Lobet et al, Infection and Immunity, Nov. 1989, 57/11:3660-3662.
Aprile et al, Canadian J. Public Health, 1966, 57:343-354.
Nencioni et al, Infection and Immunity, Feb. 1991, 59/2:625-630.
Tommaso et al, Infection and Immunity, Mar. 1996, 64/3:974-979.
Partidos et al, Immunology, 1996, 89:483-487
Lycke et al, Eur. J. Immunology, 1992, 22:2277-2281.
Douce et al, PNAS, USA, Feb. 1995, 92:1644-1648.
Podda et al, J. Exp. Med., Sep. 1990, 172:861-868.
Burnette et al, Infection and Immunity, Nov. 1991, 59/11:4266-4270.
Loosmore et al, Infection and Immunity, Jun. 1993, 61/6:2316-2324.
Farizo et al, Infeection and Immunity, Jul. 2000, 68/7:4049-4054.
Jobling et al, J. Bacteriology, Jul. 2001, 183/13:4024-4032.
Yokomizo et al, Vet. Immunol. and Immunopathol., 2002, 87:291-300.
Sanchez et al, JBC, Sep. 6, 2002, 277/36:33369-33377.
Bartley et al, PNAS USA, Nov. 1989, 86:8353-8357.
Bergstrand H., Andersson I., Nystrom I., Pauwels R., Bazin H. (1983) The Non-specific enhancement of allergy. II. Precipitation of anaphylacticin vitroresponse capacity and serum IgE and IgG2a antibody synthesis in primed but non-responding rats by injection of alum. Allergy 38:247-260.
Cogne M., Ballett J.J. Schmitt C., Bizzini B. (1985) Total and IgE antibody levels following booster immunization with aluminum adsorbed and nonadsorbed tetanus toxoid in humans. Ann. Allergy 54:148-151.
Nagel J., Svec D., Waters T., Fireman P. (1977) IgE Synthesis in Man: I. Development of specific IgE antibodies after immunization with Tetanus-Diphtheria (Td) toxoids. J. Immunol. 118:334-341.
Hedenskog S., Bjorksten B., Blennow M., Granstrom G., Granstrom M. (1989) Immunoglobulin E response to pertussis toxin in whooping cough and after immunization with a whole cell and an acellular pertussis vaccine. Int. Arch. Allergy Appl. Immunol. 89:156-161.
Medical Research Council (1951) Br. Med. J. 2:1464-1472. (p. 1471).
Medical Research Council (1956) Br. Med. J. 2:454-462.
Medical Research Council (1959) Br. Med. J. 1:994-1000.
Fine P.E., Clarkson J.A. (1987) Reflections on the efficacy of pertussis vaccines. Rev. Infect. Dis. 9:866-883.
Kanai K. (1980) Japan's experience in pertussis epidemiology and vaccination in the past thirty years. Jpn. J. Med. Sci. Biol. 33:107-143.
Miller D.L. Alderslade R., Ross E.M. (1982) Whooping cough and whooping cough vaccine: the risks and benefits debate. Epidemiol. Rev. 4:1-24.
Romanus V., Jonsell R., Bergquist S.O. (1988) Pertussis in Sweden after the cessation of general-immunization in 1979. Pediatr. Infect. dis. 6:364-371.
Munoz J.J., Arai H., Bergman K., Sadowski P.L. (1981) Biological activities of crystalline pertussigen fromBordetella pertussis. Infect. Immun. 33:820-826.
Marwick C. (1988) Pertussis vaccines: Trials and Tribulations. JAMA 259:2057-2059.
Storsaeter J., Hallander H., Farrington C.P., Olin P., Molby R., Miller E. (1990) Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 8:457-461.
Loosmore, S. Zealey, G., Cockle S. Boux, H., Chong, P., Yacoob, R. and Klein, M. (1993) Characterization of pertussis toxin analogs containing mutations in B-oligomer subunits. Infect. Immun. 61:2316-2324.
Lobet Y ., Cieplak W., Smith S.G., Keith J.M. (1989) Effects of mutations on enzyme activity and immunoreactivity of the S1 subunit of pertussis toxin. Infect. Immun. 57:3660-3662.
Loosmore S., Cockle S., Zealey G., Boux H., Cockle S., Radika K., Fahim R., Zobrist G., Yacoob R.K., Chong P., Yao F.L., Klein M. (1990) Engineering of genetically detoxified pertussis toxin analogs for development of a recombinant whooping cough vaccine. Infect. Immun. 58:3653-3662.
Nencioni L., Pizza M., Bugnoli M., DeMagistris T., Di Tomasso A., Giovannoni F., Manetti R., Marsili I., Matteucci G., Nucci D., Olivieri R., Pileri P., Presentini R., Villa L., Kreeftenberg J.G., Silvestri S., Tagliaube A., Rappuoli R. (1990) Characterization of generically inactivated pertussis toxin mutants: Candidates for a new vaccine against whooping cough. Infect. Immun. 58:1308-1315.
Burnette, W.N., Cieplak W., Mar V.L. Kaljot K.T., Sato H., Keith J.M. (1988) Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope. Science 242: 72-74.
Pizza M., Covacci A., Bartolini A., Perugini M., Nencioni L., DeMagistris T., Villa L., Nucci D., Manetti R., Bugnoli M., Giovannoni F., Olivieri R., Barbieri J., Sato H., Rappuoli R. (1989) Mutants of pertussis toxin suitable for vaccine development. Science 246:497-499.
Podda A., Nencioni L., Demagistris M., Di Tomasso A., Bossu P., Nuti S., Pileri P., Peppoloni S., Bugnoli M., Ruggiero P., Marsili I., D'Errico A., Tagliabue A., Rappuoli R. (1990) Metabolic, humoral and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G. J. Exp. Med. 172:861-868.
Milis K.H.G., Barnard A., Watkins J., Redhead K. (1993) Cell-mediated immunity toBordetella pertussis: Role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect. Immun. 61:399-410.
Redhead K., Watkins J., Barnard A., Mills K.H.G. (1993) Effective immunization againstBordetella pertussisrespiratory infection in mice is dependent on induction of cell-mediated immunity. Infect. Immun. 61:3190-3198.
De Magistris M., Romano M., Nuti S., Rappuoli R., Tagliabue A. (1988) Dissecting human T cell responses againstBordetellaspecies. J. Exp. Med. 168:1351-1362.
Gearing A.J.H., Bird C.R., Redhead K., Thomas M. (1989) Human cellular immune responses toBordetella pertussisinfection. FEMS Microbiol. Immunol. 47:205-212.
Tomoda T., Ogura H., Kurashige T. (1991) Immune responses toBordetella pertussisinfection and vaccination. J. Inf. Dis. 163:559-563.
Petersen J.W., Ibsen P.H., Bentzon M.W., Capiau C., Heron I. (1991) The cell mediated and humoral immune response to vaccination with acellular and whole cell pertussis vaccine in adult humans. FEMS Microbial. Immunol. 76:279-288.
Podda A., DeLuca E., Titone L., Casadel A., Cascio A., Peppoloni S., Volpini G., Marsili I., Nencioni L., Rappuoli R. (1992) Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: Safety and immunogenicity in 12-to-24 and 2-to-4 month old children. J. Pediatr. 120:680-685.
Pod
Boux Heather A.
Gajewczyk Diane M.
Klein Michel H.
Novak Anton
Minnifield Nita
Sanofi Pasteur Inc.
Sanofi Pasteur Inc.
LandOfFree
Proteinaceous adjuvants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proteinaceous adjuvants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteinaceous adjuvants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3607262